期刊文献+

调整给药方案对他克莫司低谷浓度肝移植患者的影响 被引量:2

Effect of Adjusting Dosage Regimen on Trough Concentration of Tacrolimus in Patients Underwent Liver Transplantation
原文传递
导出
摘要 目的:研究他克莫司在低谷浓度肝移植患者的药动学,并在每天总药量不增加的前提下,调整给药方案,使患者的谷浓度达到有效浓度范围。方法:对6例低谷浓度的肝移植患者进行药动学研究,将每12小时给药1次改为每8小时给药。采用微粒子酶免疫分析法(MEIA)测定血药浓度,比较给药方案调整前、后他克莫司谷浓度。结果:调整后的他克莫司平均谷浓度高于调整前的谷浓度(P<0.05),他克莫司的平均谷浓度由调整前的5.8μg.L-1升至调整后的7.8μg.L-1,升高了23.3%。结论:对于他克莫司低谷浓度的肝移植患者,在不增加日给药剂量的前提下,可以通过缩短给药间隔增加谷浓度,使血药浓度更加平稳。 OBJECTIVE: To study the pharmacokinetics of lower trough concentration of tacrolimus in patients underwent liver transplantation, and to adjust dosage regimen on the basis of unaltered daily dose of drugs in order to reach effective trough concentration range of tacrolimus. METHODS: 6 patients with trough concentration of tacrolimus beyond effective range were included in patients with low trough concentration. The pharmacokinetics of tacrolimus was studied. Patients were given medicine every 8 hours instead of every 12 hours. The blood concentration was determined by microparticle enzyme immunoassay (MEIA). The trough con- centration of tacrolimus after adjustment was compared with before adjustment. RESULTS: In dosage regimen of giving medicine every 8 hours, the trough concentration of tacrolimus was higher than before adjustment (P〈0.05). Mean trough concentration of FK506 increased to 7.8 μg·L-1 from before adjustment of 5.8 μg·L-1. Mean trough concentration of FK506 increased by 23.3%. CONCLUSIONS: It's a rapid effective and safe measure to raise trough concentration by shortening the dosing interval under the same daily total administration dose.
作者 张弋 沈中阳
出处 《中国药房》 CAS CSCD 北大核心 2010年第46期4357-4358,共2页 China Pharmacy
关键词 他克莫司 肝移植 谷浓度 药动学 给药方案 Tacrolimus (FK506) Liver transplantation Trough concentration Pharmacokinetics Dosage regimen
  • 相关文献

参考文献6

二级参考文献45

  • 1夏东亚,刘龙,郭涛,蒋苓,段万玲.他克莫司在肾移植患者的体内药动学[J].中国药学杂志,2004,39(10):778-780. 被引量:3
  • 2吴家清,刘东,唐斌,李琴,蒙善东,黎程.联苯双酯对肾移植患者FK506血浓度的影响[J].广东医学,2005,26(2):207-208. 被引量:12
  • 3尚亚飞,刘昌,吕毅,马锋.葡萄柚汁对FK506血药浓度的影响[J].山东医药,2006,46(32):30-31. 被引量:7
  • 4Zahir H, Nand RA, Brown KF. Validation of methods to study the distribution and protein binding of taerolimus in human blood [J] . Journal of Pharmacological and Toxicological Methods, 2001,46(1) : 27.
  • 5Victor W,Oelleric HM.New developments in the immunosuppressive drug monitoring ofcyclosporine, tacrolimus, and azathioprine [J ] . Clinical Biochem istry, 2001, 34(1) :9.
  • 6Ihor B,Dawna D,Qais A. Effect of low and high fat meals on Tacrolimus absorption following 5 mg single oral doses to healthy human subjects [J]. Clin Pharmacol ,2001, 41(2) : 176.
  • 7Napoli KL.Is Microparticle enzyme linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant Recipients[J ] . Ther Drug Monit, 2006,28(4) : 491.
  • 8Regazzi MB, Renaldi M, Molinaro M, et al. Clinical pharmacokinetics of tacrolimus in heart transplant recipients [J ]. Ther Drug Monit, 1999, 21(1) :2.
  • 9Borrows R, Chusney G, Loucaidou M, et al. Tacrolimus monitoring in renal transplantation: a comparison between high - performance liquid chromatography and immunoassay [J] .Transplantation Proceedings, 2005, 37(4) :1 733.
  • 10Chena YL, Hirabayashi H, Akhtar S, et al. Simultaneous determination of three isomeric metabolites of tacrolimus(FK506) in human whole blood and plasma using high performance liquid chromatography - tandem mass spectrometry [J ] .Journal of Chromatography B, 2006,830(2) :330.

共引文献55

同被引文献36

  • 1焦正,杨洁,张明,施孝金.高效液相色谱法测定人血浆中咪唑立宾的浓度[J].中国新药与临床杂志,2006,25(7):489-491. 被引量:10
  • 2顾健,张春燕,李玉珍.他克莫司治疗药物监测进展[J].中国药学杂志,2007,42(1):6-9. 被引量:14
  • 3肖力,任斌,陈小陆.荧光偏振法测定去甲万古霉素血药浓度[J].齐齐哈尔医学院学报,2007,28(3):315-316. 被引量:9
  • 4Oellerich M, Hon, Armstrong VW. The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments [ J ]. Ther Drug Monit, 2006,28(6) :720-725.
  • 5Khoschsorur G, Fruehwirth F, Zelzer S, et al. comparison of fluorescent polarization immunoassay ( FPIA ) versus HPLC to measure everolimus blood concentrations in clin- ical transplantation [ J ]. Clin Chim Acta, 2007,380 ( 1/ 2) :217-221.
  • 6Taylor PJ, Franklin ME, Graham KS, et al. A HPLC-mass spectrometric method suitable for the therapeutic drug mo- nitoring of everolimus [ J ]. J Chromatogr B, 2007,848 (2) :208-214.
  • 7Einecke G, Mai I, Fritsche L, et al. the value of C2 moni- toring in stable renal allograft recipients on maintenance immunosuppression [ J ]. Nephrol Dial Transplant, 2004, 19( 1 ) :215-222.
  • 8Umezawa Y, Ozawa A. Optimal time for therapeutic drug monitoring of cyclosporine microemulsion in patients with psoriasis [ J ]. Int J Dermato1,2007,46 ( 7 ) : 763-766.
  • 9Mathew BS, Fleming DH, Jeyaseelan V, et al. Alimited sampling strategy for tacrolimus in renal transplant pa- tients [ J ]. Br J Clin Pharmacol, 2008,66 (4) :467-472.
  • 10Crettol S, Venetz J-P, Fontana M ,et al.CYP3A7, CYP3A5, CYP'3A4 and ABCBlgenetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipi-ents [ J ]. Ther Drug Monit,2008,30 (6) :689-699.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部